A5076327984- Genetic and Kidney Cyst Diseases
- Biomedical Research and Pathophysiology
- Genetic Syndromes and Imprinting
- Organ Donation and Transplantation
- Renal cell carcinoma treatment
- Parathyroid Disorders and Treatments
- Diet and metabolism studies
- Vascular Malformations and Hemangiomas
- Electrolyte and hormonal disorders
- Glycogen Storage Diseases and Myoclonus
- Dialysis and Renal Disease Management
- Renal Diseases and Glomerulopathies
- Renal and related cancers
- Folate and B Vitamins Research
- Pharmacological Effects and Toxicity Studies
- Sulfur Compounds in Biology
- Renal and Vascular Pathologies
- Restless Legs Syndrome Research
- Inflammatory Bowel Disease
- Pediatric Urology and Nephrology Studies
- Eosinophilic Esophagitis
- Nuclear Structure and Function
- Fetal and Pediatric Neurological Disorders
- Neurological and metabolic disorders
- Microscopic Colitis
University Medical Center Groningen
2020-2025
University of Groningen
2020-2025
The Mayo Imaging Classification was developed to predict the rate of disease progression in patients with autosomal dominant polycystic kidney disease. This study aimed validate its ability outcomes a large multicenter cohort.
A substantial number of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) undergo a nephrectomy, especially in work-up for kidney transplantation. Currently, there is no evidence-based algorithm to guide clinicians which should the optimal timing this procedure, or preferred surgical technique. This systematic review-based consensus statement aimed answer important questions regarding nephrectomy ADPKD. literature review was performed and extended meta-analysis when...
The only therapy to ameliorate disease progression in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist. Real-life data on long-term tolvaptan are sparse and limited by restricted follow-up, small patient groups, or lack of control group. We studied the effect kidney function growth real-life controls. Moreover, we investigated determinants treatment efficacy. Data from prospective DIPAK cohort retrospective OBSERVA were...
Background: Risk stratification tools for Autosomal Dominant Polycystic Kidney Disease (ADPKD) predict kidney outcomes on a group level but lack precision in individuals. Methods: We assessed the value of adding 13 prognostic biomarkers to established risk factors (sex, age, estimated glomerular filtration rate (eGFR), systolic blood pressure, Mayo Imaging Class (MIC), and mutation type) predicting disease progression. included 596 patients from DIPAK (Developing Intervention strategies halt...
ABSTRACT Background Dysregulated energy metabolism is a recently discovered key feature of autosomal dominant polycystic kidney disease (ADPKD). Cystic cells depend on glucose and are poorly able to use other sources such as ketone bodies. Raising body concentration reduced progression in animal models diseases. Therefore, we hypothesized that higher endogenous plasma beta-hydroxybutyrate (BHB) concentrations associated with patients ADPKD. Methods We analyzed data from 670 ADPKD...
Introduction: There is no consensus if nor when a native nephrectomy should be performed in the workup for kidney transplantation ADPKD patients. In our PKD Expertise Center, restrictive approach pursued which only patients with severe complaints, i.e., case of serious volume-related lack space allograft, recurrent cyst infections, persistent bleedings, or chronic refractory pain. We analyzed retrospective cohort study whether this justified. Methods: All who received between January 2000...
In selected ADPKD patients, a nephrectomy is required in the work-up for kidney transplantation. Because impact of this procedure unknown, we investigated effect pre-transplantation on quality life group.In retrospective cohort study all ≥ 18 years, who received transplantation 2 expertise centers between January 2000 and 2016, were asked to participate. Quality was assessed using three validated questionnaires time points. Nephrectomy performed preparation transplantation.Two hundred...
Abstract Background and Aims Currently, the only available therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist. Real-life data on tolvaptan treatment effect sparce, several limitations including restricted follow-up, relatively small patient groups, no control or reported function without total volume. We studied, therefore, long-term of as well growth large number real-life ADPKD controls....
Abstract Background and Aim While major efforts were made studying the complex etiology of inflammatory bowel disease (IBD) including environmental factors, less is known about underlying causes leading to heterogeneous highly variable course disease. As cigarette smoking cessation best‐known factor with beneficial effect in Crohn's (CD), more exposome factors are likely involved. Further insights into role heterogeneity might not only further knowledge pathways, but also allow for better...
Abstract Background and Aims Determining prognosis in patients with autosomal dominant polycystic kidney disease (ADPKD) heavily relies on the height-adjusted total volume (HtTKV) Mayo classification. This classification predicts outcomes a group level but lacks precision individual patients. Recently, several urine blood biomarkers have demonstrated prognostic value ADPKD, independent of HtTKV baseline eGFR. study compares various to aid selection when developing novel risk stratification...
Chronic Kidney Disease (CKD), is often detected late due to its asymptomatic nature in the early stage of disease. Overproduction reactive oxygen species contributes various pathological processes through oxidative stress (OS), impacting on cellular structures and functions with previous studies suggesting a link between OS CKD progression. This study investigated association serum peroxiredoxin-4 (Prx4), biomarker stress, development general population.
ABSTRACT Background The only treatment proven to be renoprotective in autosomal dominant polycystic kidney disease (ADPKD) is a vasopressin V2-receptor antagonist (V2RA). However, aquaresis-associated side effects limit tolerability. We investigated whether salt and/or protein intake influences urine volume and related endpoints V2RA-treated ADPKD patients. Methods In this randomized, controlled, double-blind, crossover trial, patients treated with maximally tolerated dose of V2RA were...
Although disease course is variable in patients with autosomal dominant polycystic kidney (ADPKD), the majority of need replacement therapy, which (pre-emptive) transplantation modality first choice.1Spithoven E.M. Kramer A. Meijer E. et al.Renal therapy for (ADPKD) Europe: prevalence and survival - an analysis data from ERA-EDTA Registry.Nephrol Dial Transplant. 2014; 29: iv15-iv25https://doi.org/10.1093/ndt/gfu017Crossref PubMed Scopus (143) Google Scholar It assumed that due to their...
Abstract BACKGROUND AND AIMS In some patients with autosomal dominant polycystic kidney disease (ADPKD), one or both native kidneys are removed in the work-up for transplantation. There is no consensus if and when a nephrectomy should be performed. Some centers advocate to routinely perform (bilateral) prevent complications associated post-transplantation period. our ADPKD expertise center, restrictive approach pursued: only performed case of serious volume related complaints, lack space...
Abstract Background and Aims A dysregulated energy metabolism is a key feature of Autosomal Dominant Polycystic Kidney Disease (ADPKD), characterized by cystic cells being dependent on glucose poorly able to use other sources such as ketone bodies. Besides providing energy, bodies, especially beta-hydroxybutyrate, can act signaling metabolites reduce inflammation oxidative stress. In experimental studies, raising body concentration reduced disease progression. Therefore, we hypothesized that...
Bais, Thomas; Geertsema, Paul; Knol, Martine G.; van Gastel, Maatje D.; Meijer, Esther; Gansevoort, Ron T.; On Behalf of the DIPAK Consortium. Author Information
Abstract BACKGROUND AND AIMS In autosomal dominant polycystic kidney disease (ADPKD), the enlarged kidneys can cause clinical problems, for instance pain or gastro-intestinal complaints, recurrent infections, a lack of space transplant. selected ADPKD patients, nephrectomy is required in work-up transplantation. Currently, it unknown how this procedure affects quality life (QoL), nor leaving both situ influences wellbeing. The aim study was to investigate impact pretransplantation on APDKD...